CRISPR Therapeutics AG CRSP
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -111.44M | -91.15M | -122.93M | -130.61M | -106.44M |
| Total Depreciation and Amortization | 4.24M | 4.28M | 4.32M | 5.66M | 4.43M |
| Total Amortization of Deferred Charges | 736.00K | 848.00K | -- | -- | -- |
| Total Other Non-Cash Items | 14.63M | 6.23M | 25.12M | 9.76M | 6.47M |
| Change in Net Operating Assets | 2.15M | -3.70M | -15.41M | 22.64M | 10.91M |
| Cash from Operations | -89.68M | -83.50M | -108.90M | -92.55M | -84.63M |
| Capital Expenditure | -414.00K | -648.00K | -504.00K | -517.00K | -74.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -13.67M | -55.01M | -410.24M | 37.72M | -119.15M |
| Cash from Investing | -14.09M | -55.66M | -410.74M | 37.20M | -119.23M |
| Total Debt Issued | 0.00 | 0.00 | 600.00M | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4.45M | 8.30M | 6.16M | 116.41M | 296.77M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -1.12M | -14.25M | -- | -- |
| Cash from Financing | 4.45M | 7.18M | 591.91M | 116.41M | 296.77M |
| Foreign Exchange rate Adjustments | 6.00K | 6.00K | -32.00K | 1.00K | -27.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -99.31M | -131.97M | 72.24M | 61.06M | 92.88M |